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Introduction
Autism represents a broadly defined 
disorder of behavior and cognition with 
onset prior to age 3 affecting the core 
domains of language and social devel-
opment and involving abnormal repeti-
tive and restrictive behaviors. Because 
autism is characterized by groups of 
symptoms and signs even in its narrow-
est conception, it is a highly variable 
neurodevelopmental syndrome and not 
a unitary condition. Children diagnosed 
with autism differ significantly in sever-
ity along many cognitive and behavioral 
dimensions, spawning the term autism 
spectrum disorder (ASD) to emphasize 
its full scope.
Basic genetic and neuroscience 
research in ASD has grown exponen-
tially, reflecting a remarkable trajec-
tory that likely represents many factors, 
including public awareness and the 
realization that ASDs are a significant 
cause of lifetime neuropsychiatric mor-
bidity, affecting nearly 1/150 live births. 
However, in contrast with many other 
disorders of the brain, for example neu-
rodegenerative diseases such as Par-
kinson’s or Alzheimer’s diseases, autism 
lacks any clear unifying pathology at the 
molecular, cellular, or systems level. Fur-
thermore, although ASDs appear to be 
highly heritable overall, their underlying 
genetic etiology is complex, likely involv-
ing many genes, some of which may 
represent common genetic variation, as 
well as potential interactions with envi-
ronmental factors. Thus, ASD research 
has to contend with not only the com-
plexity and broadness of the phenotype 
itself, which encompasses the biological 
basis of human social interactions and 
language, but genetic and environmental 
complexity as well. Despite these chal-
lenges, measurable progress has been 
achieved, placing several key questions 
into relief.
Autism Is Heritable but Genetically 
Heterogeneous
Three decades of research on autism 
involving twin and family studies support 
a significant genetic contribution to its eti-
ology. However, high heritability does not 
necessarily imply a particular model of 
genetic transmission or an easily identifi-
able major gene causing the disorder. On 
the contrary, the last decade of research 
in autism genetics reveals significant 
genetic heterogeneity. For example, sev-
eral dozen distinct genetic disorders or 
identified chromosomal abnormalities can 
result in autism, including Joubert’s syn-
drome, Rett’s syndrome, tuberous scle-
rosis, Fragile X syndrome, and maternally 
inherited duplications of chromosome 
15q11-13, the latter two each account-
ing for 1%–2% of ASD cases (Veenstra-
Vanderweele et al., 2004). In all, known 
rare chromosomal disorders and genetic 
mental retardation syndromes account 
for ~10% of ASD, each single cause con-
tributing to no more than 1% of cases 
on average (Abrahams and Geschwind, 
2008).
The existence of considerable genetic 
heterogeneity is also supported by sev-
eral dozen genetic linkage studies over 
the last decade, which have often iden-
tified nonoverlapping regions of inter-
est and largely failed to formally repli-
cate autism linkage findings at the level 
of genome-wide significance. There 
are a few notable exceptions including 
regions on chromosome 7q21-35, sup-
ported by meta-analysis (Badner and 
Gershon, 2002), and chromosome 17q, 
which has been replicated at genome-
wide significance (Cantor et al., 2005). A 
recent large collaborative genome scan 
by the Autism Genome Project (AGP) 
of nearly 1200 sibling pairs with ASD 
(Szatmari et al., 2007) identified several 
regions of interest, including chromo-
some 11, but did not identify one region 
at genome-wide significance, despite a 
marked increase in sample size over the 
largest previous studies. Similarly, the 
homozygosity mapping collaborative for 
autism (HMCA; Morrow et al., 2008) did 
not report genome-wide significant loci 
shared by two or more of the approxi-
mately 80 consanguinous families, con-
sistent with the existence of many dis-
tinct autism loci in this population as 
well. However, HMCA investigators were 
able to identify six independent homozy-
gous deletions segregating with autism 
in this unique cohort, implicating several 
new genes in autism susceptibility while 
again highlighting the genetic heteroge-
neity of ASD (Morrow et al., 2008).
Whole genome association (WGA) 
studies using various microarray plat-
forms are beginning to replace linkage 
studies in the analysis of complex (non-
Mendelian) genetic disease including 
ASD. These genome-wide association 
analyses test the association of common 
single-nucleotide variations (SNPs) with 
disease in a population. If a disease like 
autism is primarily caused by rare muta-
tions in certain chromosomal regions, 
WGA is unlikely to be adequately pow-
ered to identify most of these, whereas 
linkage may be powered to identify the 
chromosomal region where they reside. 
Subsequent resequencing of genes 
within a linkage region would then be 
necessary to identify the actual causal 
gene. No large WGA studies have yet 
been published in ASD, but studies of 
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common variant association in link-
age regions suggest that analyses per-
formed will be underpowered and that 
at least a doubling in sample size (many 
thousands of cases, similar to studies of 
type I diabetes) will be needed to iden-
tify more than a few loci at genome-wide 
significant association.
These results echo findings in other 
common diseases with a complex 
genetic basis, in which early underesti-
mation of heterogeneity and overestima-
tion of the magnitude of risk imparted 
by any given susceptibility allele led to 
underestimates of sample sizes needed 
for adequate power to detect common 
variant associations. From this perspec-
tive, the results of linkage and associa-
tion studies in autism imply that attain-
ing massive sample sizes through large 
collaborative efforts and sample shar-
ing—for example, through the Autism 
Genetic Resource Exchange (AGRE) 
and the Autism Genome Project (AGP) 
(Geschwind et al., 2001, Szatmari et al., 
2007)—will be necessary to successfully 
find many common susceptibility genes.
Rare or De Novo Mutations in ASD
Perhaps the most remarkable advance in 
ASD genetics in the last year was driven 
by the earlier discovery that regional 
variations in gene copy number, either 
heritable or arising de novo (not seen 
in parents), are a significant source of 
genetic variation in humans (Sebat et al., 
2004). Copy number variation (CNV) is a 
form of structural variation in the genome 
in which there is a gain or loss in a chro-
mosomal region greater than 1 kilobase 
(kb) in size, in contrast to the more com-
mon SNPs, which are changes at one 
base pair of DNA. Recently, Sebat et al. 
(2007) identified de novo CNVs in 3% of 
autistic children from multiplex families 
(having two or more affected members) 
and in 10% of autistic children from 
simplex families (having one child with 
ASD). These findings were presaged by 
previous studies using lower-resolution 
methods that identified a number of 
large chromosomal anomalies associ-
ated with ASD and mental retardation 
(Jacquemont et al., 2006), including a 
duplicated region on chromosome 15q 
identified more than a decade ago (Veen-
stra-Vanderweele et al., 2004). Perhaps 
because some of these mutations were 392 Cell 135, October 31, 2008 ©2008 Elsevrare, large, affected other organ systems 
in addition to the central nervous system, 
or simply seemed to be special cases, 
this mechanism was largely unappreci-
ated as a potential cause of idiopathic 
autism. The CNVs identified by Sebat et 
al. (2007) were composed of deletions 
(70%) and duplications (30%) of DNA 
fragments ranging from 160 kb to several 
megabases in size, thus containing seg-
ments from the size of a single gene to 
chromosomal regions harboring a dozen 
or more genes. Such genomic level de 
novo mutational events were only found 
in 1% of control individuals and were 
all duplications rather than the typically 
more deleterious deletions observed in 
ASD (Sebat et al., 2007). Remarkably, 
most of the CNVs were unique, providing 
an indication that a significant fraction 
of ASD may be accounted for by rare, 
essentially private, mutations in simplex 
(one affected child) autism families. Sim-
ilarly, the large AGP linkage study identi-
fied a handful of rare, likely causal CNVs 
using a lower-resolution platform (Szat-
mari et al., 2007).
It is too early to predict with certainty 
from these data the contribution of de 
novo CNVs to ASD susceptibility. Larger 
sample sizes ascertained from indepen-
dent, clearly defined populations will be 
necessary to accurately define the role of 
CNVs. Sample characteristics are impor-
tant: de novo mutations are observed 
more frequently in those with more 
severe intellectual disability or dysmor-
phology (Jacquemont et al., 2006). The 
contribution of de novo CNVs is also sig-
nificantly less in multiplex families hav-
ing two or more autistic children (Sebat 
et al., 2007), a finding confirmed in sub-
sequent studies (Weiss et al., 2008; Mar-
shall et al., 2008). Because the number 
of CNVs detected is clearly related to the 
resolution of the microarrays used, the 
contribution of known CNVs to autism 
is expected to increase beyond 10% 
as microarray probe density increases. 
Similarly, single base pair mutations 
in a few genes encoding the synaptic 
adhesion proteins neuroligins 3 and 4, 
the voltage-gated calcium ion channel 
CaV1.2, the tumor suppressor PTEN, and 
shank3, a cytoplasmic binding partner 
of the neuroligins, have been identified in 
rare cases of ASD. The advent of efficient 
partial genome sequencing will more ier Inc.fully clarify the contribution of rare sin-
gle-nucleotide variants to ASD. It should 
be emphasized that the contribution of 
inherited CNVs as a source of more com-
mon genetic contributions to ASD has 
not been explored in depth. This will be 
important because some heritable CNVs 
may have subtle phenotypic effects and 
will contribute to common variations in 
cognition and behavior.
The occurrence of rare de novo muta-
tions in ASD raises important issues 
regarding mechanisms causing muta-
tions (Lupski, 2007). Paternal age is asso-
ciated with increasing point mutations in 
sperm, and complex genetic conditions 
associated with increasing paternal age 
may have a higher percentage of new 
mutations. New mutations may be par-
ticularly pronounced in the offspring of 
older fathers, who may be a reservoir for 
such de novo events. Notably, advanced 
paternal age has recently been shown to 
significantly increase risk for ASD in two 
distinct patient samples (Cantor et al., 
2007; Reichenberg et al., 2006). These 
data suggest one of many potential 
mechanisms through which environmen-
tal factors could play a role in creating 
de novo genetic events causing autism, 
that is, accumulation of mutations in the 
male germline. Such factors could occur 
in isolation or in conjunction with genetic 
susceptibility loci. In the latter case, cer-
tain inherited haplotypes, for example, 
could render specific regions more vul-
nerable to mutagens, thus increasing the 
frequency of mutational events. Alterna-
tively, certain regions may be more vul-
nerable to other environmental factors 
that could affect chromatin structure or 
gene expression, leading to epigenetic 
causes of autism (Jiang et al., 2004).
Multigenic versus Major Gene 
Contributions
Currently, the predominant genetic model 
supposes the presence of multigenic 
inheritance of common polymorphisms 
contributing to autism risk in multiplex 
families (Abrahams and Geschwind, 
2008). At face value, the paucity of mul-
tigenerational pedigrees segregating 
ASD argues against Mendelian, more 
specifically, dominant inheritance. How-
ever, Wigler and colleagues (Zhao et al., 
2007) recently reassessed this notion 
based on the identification of rare CNVs 
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as significant contributors to autism 
genetic risk and the strikingly higher inci-
dence in males (4:1 male-female ratio). 
The model is based on a formal analysis 
of recurrence risk in multiplex families 
and is consistent with a significant con-
tribution from two major risk categories: 
low-risk families in which there is little 
genetic loading for autism in other family 
members but in which the proband car-
ries highly penetrant de novo mutations 
(accounting for about half of the cases) 
and higher-risk families consistent with 
dominant inheritance in males (account-
ing for about one-third of cases). This 
model fits the family data collected by 
several groups if the high-risk alleles have 
lower penetrance with respect to the ASD 
phenotype in females. Future gene hunt-
ing efforts will provide an empirical test 
of this model. Nevertheless, the current 
data are consistent with the notion that 
autism spectrum disorders are caused by 
a higher proportion of rare mutations than 
previously anticipated and that the con-
tribution of common variants will mostly 
consist of alleles with small effect sizes.
Identification of Common Genetic 
Variants
Moving from genetic linkage studies 
to identifying the multiple causal vari-
ants that likely underlie chromosomal 
regions with the strongest linkage sig-
nals remains a challenge. It may be that 
rare mutations underlie these signals and 
identifying these will require large-scale 
resequencing of the entire region in large 
numbers of cases and controls. In sev-
eral cases, the identification of causal 
common variation has been illusory 
despite strong overlying linkage signals, 
supporting the potential role of multiple 
rare mutations or many common vari-
ants, each of small effect size.
Even as the current strategies identify 
reproducible underlying genetic variants, 
the question still remains to what aspect 
of the ASD phenotype are they related? 
Similarly, the striking phenotypic het-
erogeneity and clinical variability even 
among twins suggest that distinct forms 
of autism may exist or that distinct 
genetic risk factors may be related to 
specific phenotypic features. This notion 
is brought into focus in the recent HMCA 
study (Morrow et al., 2008), where rare, 
potentially disease-causing mutations in 
Figure 1. Common and Rare Genetic Variations and the Heterogeneity of Autism
Susceptibility to autism spectrum disorder (ASD) may in some cases reflect the contribution of normal 
variation in heritable, potentially distinct core components of autism (endophenotypes). This simplified 
model (A) depicts how a variety of risk variants, large and small, may contribute to ASD in aggregate 
(B). The notion of hetereogeneous genetic mechanisms acting in different patients is captured by three 
individual examples depicted by circles (C).
(A) Normal variations in language, social behavior, and repetitive-restrictive behavior are illustrated as 
overlapping but with distinct functions (blue and orange demarcate the highest level of functioning and 
progressive abnormality, respectively). In this scheme, moderate abnormality in all three areas is neces-
sary to be diagnosed with autism, but abnormality in one area, for example language, leads to a more cir-
cumscribed condition, such as specific language impairment. Patients with Asperger’s syndrome would 
have normal language but would lie in the orange zone for the other two components. Each of these 
heritable cognitive-behavioral components (endophenotypes), although genetically complex, is likely to 
be less heterogeneous than the syndrome of autism. These endophenotypes can be studied separately 
to increase power to detect common genetic risk variants.
(B) The contribution of genetic or environmental factors is emphasized by size or position of each repre-
sentative weight. Mendelian mutations, such as de novo CNVs, are depicted by a large ball because they 
are considered causal in many cases and would tip the balance, placing an individual essentially into the 
orange zone in all categories shown in (A) (pleiotropy), resulting in autism. 
The reality, however, is that there are few mutations that act alone or are fully causal (green circle 
in C.) Many mutations, including those that are recurrent, are not fully penetrant, and some patients 
have more than one de novo CNV. Similarly, most mutations, even rare mutations such as those in 
the gene encoding neuroligin 4, or recurrent mutations such as del (16p), show variable expressivity, 
resulting in developmental delay or mental retardation in some individuals and autism in others. So, 
the environment or other common variants that might modulate social behavior or language could be 
tipping the balance toward autism in a child who would otherwise have had mild or moderate mental 
retardation (blue circle in C). In other cases, multiple common variants, each with a small effect and 
related to different components, would push an individual toward the right of the distribution and 
along with environmental or epigenetic factors would result in an individual with ASD (multicolored 
circle in C). Each of these scenarios, or a combination of the three, may be acting in a given individual 
with autism. Defining the extent to which each contributes on a population level to ASD is a goal of 
current genetic research.
the gene Slc9a9 were increased in AGRE 
families with autism and epilepsy, but 
not in those without epilepsy. Genotype-
phenotype correlations will become even 
more salient as attempts are made to 
produce relevant animal models, not to 
mention the needs of families undergo-
ing prognostic counseling in the future.
Moreover, from a neurobiological per-
spective, different aspects of human cog-
nition and behavior are served by distinct 
brain regions, which are likely to be pat-
terned and maintained by distinct genetic 
factors. Thus, specific genetic risk factors 
may correspond to changes at the level of 
specific brain structures or neural systems 
that contribute to autism, such as those 
serving language or social cognition, 
rather than the broad syndrome of autism 
itself (Geschwind and Levitt, 2007; Figure 
1). These heritable components or endo-
phenotypes involving language, social 
responsiveness, or behavioral rigidity are 
also observed at higher frequency in first-
degree relatives of autistic subjects and 
can be measured as continuous, quanti-
tative variables. Compared with the cat-
egorical diagnosis of autism, approaches 
based on linking quantitative endophe-
notypes to underlying genetic risk may 
provide more power, as has been appre-
ciated in other complex genetic condi-
tions. This quantitative trait locus (QTL) 
approach has the additional benefits of 
including unaffected relatives and the full 
range of variation in a particular measured 
phenotype rather than the arbitrary cate-
gorical determination of affected (autistic) 
and unaffected (not autistic), which has 
changed over time. We and others have 
successfully used QTL mapping to iden-
tify chromosomal loci related to cognitive 
endophenotypes, such as language, non-
verbal communication, and social cogni-
tion (e.g., Alarcón et al., 2008). Moreover, 
because we postulate that these features 
involving language, social behaviors, and 
other behavioral or cognitive traits repre-
sent one end of a continuum, normal or 
otherwise (Figure 1), they are likely to be 
related to many different neuropsychiat-
ric and neurodevelopmental conditions, 
in addition to ASD.
One sign of success comes from a 
recent high-density SNP association 
analysis of the chromosome 7q language 
QTL, in which a common allele of CNT-
NAP2 was associated with a language 394 Cell 135, October 31, 2008 ©2008 Elsevendophenotype and a 160 kb deletion 
in CNTNAP2 was detected in a single 
proband (Alarcón et al., 2008). Concur-
rently, another group discovered rare 
causal de novo chromosomal variation 
and point mutations in CNTNAP2 (Bak-
kaloglu et al., 2008), and yet another 
identified common variation in CNTNAP2 
potentially associated with ASD (Arking 
et al., 2008), providing multiple converg-
ing lines of evidence for the involvement 
of CNTNAP2 in ASD. In addition, Strauss 
and colleagues had previously discovered 
a single rare recessive truncating muta-
tion in CNTNAP2 that caused a syndrome 
of focal epilepsy and neuronal migration 
abnormalities in affected individuals in 
an Amish family (Strauss et al., 2006). 
Remarkably, the majority of affected chil-
dren were also found to suffer from lan-
guage delay and ASD, further supporting 
the role of CNTNAP2 genetic variation 
related to language systems that are dis-
rupted in ASD. This work on CNTNAP2, 
in which variation in the same gene may 
lead to distinct clinical phenotypes, fur-
ther emphasizes that current notions of 
disease status based on clinical diagnos-
tic schema can create artificial boundar-
ies between conditions that may share 
similar genetic underpinnings.
Connecting Genes to Brain and 
Behavior
Most mutations known to cause autism 
are de novo mutations often involving 
multiple genes or identified genetic syn-
dromes. Common variants have been 
implicated in autism association, but 
most of these are either in small sam-
ples or have not been replicated. Nev-
ertheless, common variations in several 
genes including EN2 (Benayed et al., 
2005), the MET proto-oncogene (Camp-
bell et al., 2006), and others in addition to 
CNTNAP2 either have been implicated in 
large samples or independently repli-
cated. But none of these published asso-
ciations individually account for a large 
fraction of the genetic risk for ASD.
Considering these common variants 
and the known rare mutations, autism 
susceptibility genes appear to have many 
distinct roles in neural development and 
neuronal function, ranging from basic 
metabolism, synaptic transmission, and 
RNA splicing to neuronal migration. 
Mutations in genes implicated in these ier Inc.functional categories clearly can cause 
ASD, but how? Do known mutations 
converge on a few common molecular 
pathways or do they represent diverse 
biological etiologies, and if so, how does 
disruption of such diverse functions 
result in the syndrome of autism? The 
answer to this question goes beyond the 
boundaries of the current data. Further-
more, several of the known autism genes 
including NLGN4 clearly cause mental 
retardation, and others such as the 16p11 
CNV are associated with more general 
forms of developmental delay (Weiss et 
al., 2008), perhaps more frequently than 
they cause ASD. So how does disease 
specificity emerge?
Whatever the known molecular and 
biological functions of ASD susceptibil-
ity genes, they must converge on the 
disruption of function in brain regions 
supporting language, social cognition, 
and behavioral flexibility. This could 
involve focal gene expression of the spe-
cific gene product during development; 
when the risk allele is expressed, there 
is disruption of the cortical and subcor-
tical brain networks supporting social 
responsiveness or language. Remark-
ably, this appears to be the case for 
CNTNAP2, which is enriched in highly 
evolved, anterior regions of the develop-
ing human cerebral cortex that overlap 
with circuitry involved in the development 
of joint attention (Alarcón et al., 2008), a 
social precursor to language that is one 
of the early behaviors disrupted in ASD.
However, most known ASD sus-
ceptibility genes do not demonstrate 
such regionally restricted expression, 
so other factors must also be operat-
ing. The core areas affected in autism 
involve rapid and coherent integration 
of information from multiple, higher-
level association areas (Geschwind 
and Levitt, 2007). Such functions could 
be easily perturbed by minor, but rela-
tively widespread disruptions in neu-
ral transmission, for example, due to 
either subtle mis-wiring or synaptic 
dysfunction. Circuit mis-wiring could 
be either local or long distance and 
could be caused by myriad conditions 
such as neuronal migration abnormali-
ties, disrupted axon pathfinding, loss 
or dysfunction of local inhibitory con-
nections, or immature synaptic func-
tion, all culminating in what has been 
referred to as a developmental discon-
nection (Geschwind and Levitt, 2007). 
Thus, one would expect to find subtle, 
widespread differences in many brain 
systems in subjects with ASD, even 
those serving primary sensory func-
tions, although these may not be the 
direct cause of the core features of 
autism. Such abnormalities, however, 
may explain the differences in sensory 
processing, motor function, and sen-
sory-motor integration, in addition to 
the more global processing differences 
that have been variably associated with 
ASD (e.g., Happe and Frith, 2006).
The concepts of focal versus dif-
fuse circuit disruption are not mutually 
exclusive and both may cause different 
forms of ASD. Moreover, any unifying 
framework for understanding autism will 
necessarily involve testing hypotheses in 
autism cases with many distinct known 
etiologies. Now that we possess the 
tools to continue to identify the genes 
causing autism, the challenge is to inte-
grate these findings with the study of 
cellular physiology and brain anatomy 
and function to bridge the gap between 
genes and cognition. Given the role of 
highly adapted language and social cog-
nition systems in autism, we also need to 
clearly consider the role of human-spe-
cific cognitive specializations, carefully 
integrating model system data with stud-
ies in humans. From this perspective, 
autism is paradigmatic of the challenge 
facing those who wish to understand 
diseases affecting higher cognition—the 
challenge of integrating detailed molecu-
lar knowledge with complex circuit func-
tion in humans. As this challenge is met 
and our knowledge increases, leading to 
etiological understanding of the disor-
der, our concepts of disease boundaries 
are likely to change.ACknowledGMents
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